We greatly appreciated the recently published single-center study by Kakkos et al.
1in which they aimed “to evaluate the impact of the interval between the insertion of totally implantable venous access port system (TIVAPS) and its first use, as well as to examine the possible implication of the neutropenia-inducing potential of the chemotherapy regimens used on documented infections and consequent removal rates”. Thus, between January 2010 and December 2013, the authors prospectively included 4045 consecutive patients (median age 57 years; range: 1–89) all treated for solid tumors and requiring TIVAPS to facilitate chemotherapy administration.
- Kakkos A.
- Bresson L.
- Hudry D.
- et al.
Complication-related removal of totally implantable venous access port systems: does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year retrospective study of 4045 patients.
Eur J Surg Oncol. 2016; 43: 689-695
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Surgical Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Complication-related removal of totally implantable venous access port systems: does the interval between placement and first use and the neutropenia-inducing potential of chemotherapy regimens influence their incidence? A four-year retrospective study of 4045 patients.Eur J Surg Oncol. 2016; 43: 689-695
- Totally implantable venous access device in children with cancer lead to disfiguring scar.Pediatr Hematol Oncol. 2013; 30: 154-164
Published online: January 24, 2017
Accepted: December 10, 2016
© 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.